[ÇÑÅõÁõ±Ç ÁøÈ«±¹] Á¦¾à/¹ÙÀÌ¿À µ¥Àϸ® ´º½º
¾È³çÇϼ¼¿ä ÇÑÅõÁõ±Ç Á¦¾à¹ÙÀÌ¿À ÁøÈ«±¹ÀÔ´Ï´Ù.
¢º️ÀüÀÏ ¹Ì±¹ ÁÖ¿ä À妽º
* ´Ù¿ì -0.4% S&P Á¦¾à -0.9% ³ª½º´Ú ¹ÙÀÌ¿À +0.1%
¢º️ÇØ¿Ü Peer ÀüÀÏ ÁÖ°¡
* ¼¿Æ®¸®¿Â °ü·Ã: Pfizer -0.3% J&J -0.5% Teva -1.1% Mylan -2.8%
* »ï¼º¹ÙÀÌ¿À °ü·Ã: Lonza -0.2% Merck +0.4% Roche +1% Amgen -0.2% Biogen -0.9%
* Çѹ̾àÇ° °ü·Ã: Sanofi -0.1% Spectrum +0.3%
* º¸Å彺: Allergan -1.1% Revance Therapeutic +2.7% Evolus +5.1%
* ±âŸ: Gilead Science +0% Regeneron +0.4% Abbvie -1.2% Celgene -0.7% Eli Lilly -1.6% CSL +0.7%
¢º️±¹³» À̽´
* ¹ý¿ø, ±èÅÂÇÑ »ï¼º¹ÙÀÌ¿À ´ëÇ¥ ±¸¼Ó¿µÀå ±â°¢
* '8Á¶ ¾Æ¹Ù½ºÆ¾ ½ÃÀå' ¿À¸®Áö³Î-½Ã¹Ð·¯ ¹°¹Ø°æÀï º»°ÝÈ
* ¡°50Á¶¿ø ½ÃÀå Àâ¾Æ¶ó¡± ¼¿Æ®¸®¿Âµµ ñé ÁøÃâ
* JWÁß¿Ü, Wnt Ç÷§Æû Ç׾Ͻžà 3Á¾ ¾îµð±îÁö ¿Ô³ª
* ¿À½ºÄÚÅØ, ·ù¸¶Æ¼½º °üÀý¿° ½Å¾à ÀÓ»ó2»ó ½ÂÀÎ
* À̼ö¾ÛÁö½º "Ŭ·ÎƼ³ÀÁÖ, Á¦3 ÀÓ»ó½ÃÇè °èȹ ½ÂÀÎ"
* ÷»ý¹ý, ¹ý»çÀ§ ÆÄÇà¿¡ ¶Ç´Ù½Ã ¹ß¹¿©
¢º️ÇØ¿Ü À̽´
* ³ë¹ÙƼ½º, 2/4ºÐ±â ¸ÅÃâ¾× 117.6¾ïÝ× 4% ¼ºÀå
* ±æ¸®¾îµå, ³ë¹ÙƼ½ºÀÇ ¡®3°³ Ç×¹ÙÀÌ·¯½º ÇÁ·Î±×·¥¡¯ Àμö
* ¡®¿ÀÅ×Áñ¶ó¡¯ ù º£Ã¼Æ®º´ °ü·Ã ±¸°±Ë¾ç Ä¡·áÁ¦·Î
* As filgotinib filing nears, Gilead should nab Celgene's Otezla, analysts say.
|